NCT00220636 is a Phase 4 clinical trial of Aripiprazole in Depressive Disorder, Major, sponsored by St. Luke's-Roosevelt Hospital Center.

Who is sponsoring NCT00220636?

NCT00220636 is sponsored by St. Luke's-Roosevelt Hospital Center.

What drugs are being tested in NCT00220636?

Interventions in NCT00220636: Aripiprazole.

What condition does NCT00220636 study?

NCT00220636 studies Depressive Disorder, Major.

Is NCT00220636 still recruiting?

NCT00220636 is currently completed. Last updated 26 April 2016.

Are results published for NCT00220636?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-04-26 · How we verify

NCT00220636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression

Completed Phase 4 Results posted Last updated 26 April 2016

What this trial tests

Phase 4 trial testing Aripiprazole in Depressive Disorder, Major in 15 participants. Completed in 1 January 2008.

Timeline

1 March 2005

Primary endpoint
1 March 2007

1 January 2008

Quick facts

Lead sponsor	St. Luke's-Roosevelt Hospital Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 March 2005
Primary completion	1 March 2007
Estimated completion	1 January 2008
Sites	1 location across United States

Drugs / interventions tested

Aripiprazole (aripiprazole) — full drug profile →

Conditions studied

Depressive Disorder, Major — all drugs for Depressive Disorder, Major →

Sponsor

St. Luke's-Roosevelt Hospital Center

Who can join

Adults 18 to 70, any sex, with Depressive Disorder, Major. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hamilton Depression Rating Scale (HDRS)
Time frame: 12 weeks
Clinician rated measure of depression, mean score; this study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (\>50% decrease) Remission (score\<=7) Outcome is the number of these subjects whose depression "responded"

Sponsor's own description

This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Aripiprazole

Trials testing the same drug.

NCT06236451 — Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia · Phase 4 · completed
NCT06060886 — Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis · Phase 4 · unknown
NCT05554627 — VA Aripiprazole vs Esketamine for Treatment Resistant Depression · Phase 4 · withdrawn
NCT05814640 — Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) · Phase 1, PHASE2 · recruiting
NCT05322031 — The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia · Phase 4 · completed

Other recruiting trials for Depressive Disorder, Major

Currently open trials in the same condition.

NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting

Other St. Luke's-Roosevelt Hospital Center trials

Trials by the same sponsor.

NCT02159807 — Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects · NA · completed
NCT03195712 — Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers · completed
NCT00841451 — Pulmonary Vein Isolation Outcomes With Fish Oils · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00220636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Luke's-Roosevelt Hospital Center
Last refreshed: 26 April 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00220636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing